share_log

Catalent Launched New Service for End-to-End Supply Chain Case Management of Cell and Gene Therapies

Catalent Launched New Service for End-to-End Supply Chain Case Management of Cell and Gene Therapies

Catalent 推出用于细胞和基因疗法端到端供应链案例管理的新服务
Benzinga Real-time News ·  2023/01/24 09:24

Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the launch of its new Case Management Service, which has been specifically designed to address the unique challenges associated with the safe and timely delivery of advanced therapies to patients by providing professional supply chain oversight from program start to finish. The supply chain logistics for advanced therapy medicinal products (ATMPs), such as cell and gene therapies, is complex because of their inherent sensitivity, high value, and certain patient-specific complexities of delivering each dose. Ensuring these products are efficiently managed and correctly transported reduces the risk of potential disruption to the manufacturing schedule and, ultimately, the administration of the therapy to the patient.

为全球患者开发和供应更好的治疗方法的领先企业Catalent今天宣布推出其新的病例管理服务，该服务是专门为解决与安全和及时向患者提供先进治疗相关的独特挑战而设计的，从计划开始到结束提供专业的供应链监督。先进治疗药物产品(ATMP)的供应链物流是复杂的，因为它们固有的敏感性、高价值和特定于患者的递送每个剂量的复杂性。确保这些产品得到有效管理和正确运输，可降低生产计划潜在中断的风险，并最终降低给患者实施治疗的风险。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发